Smith & Nephew SNATS Q4 Earnings Call Highlights

4 days ago 9

MarketBeat

Mon, March 2, 2026 astatine 5:26 AM CST 8 min read

Smith & Nephew SNATS logo

Strong FY2025 finish: Underlying gross roseate 5.3% to $6.2 billion, adjusted EPS climbed 21% to $1.02, trading borderline expanded 160 bps to 19.7%, and escaped currency travel jumped 52.5% to $840 cardinal helped by a $500 cardinal buyback.
Business momentum was led by Orthopedics (Q4 underlying maturation 7.9%) driven by hep uptake, CORI robot adoption and improving knees, portion Sports Medicine/ENT grew 7.3% with associated repair surpassing $1 cardinal and Advanced Wound showed mixed results with instrumentality strength.
2026 guidance targets astir 6% integrated revenue maturation and ~8% trading nett growth; absorption expects the Integrity Orthopaedics woody (up to $450M) to beryllium marginally dilutive successful 2026 but accretive by 2028, portion notable headwinds see $60M of tariffs, $20–40M from coiled reimbursement changes and China VBP impacts.
Interested successful Smith & Nephew SNATS, Inc.? Here are 5 stocks we similar better.

Santa Rally comes aboriginal for these stocks

Smith & Nephew SNATS (NYSE:SNN) executives struck an optimistic code successful the company’s fourth-quarter and full-year 2025 results presentation, pointing to a “strong finish” that landed astatine the precocious extremity of management’s guidance for gross growth, borderline expansion, and escaped currency flow. Chief Executive Officer Deepak Nath said underlying gross roseate 5.3% for the afloat year, with each 3 concern units posting maturation supra 5%.

Nath highlighted continued spot successful Sports Medicine and ENT—particularly associated repair—and “meaningful progress” successful U.S. Orthopedics, including hips and trauma, portion acknowledging that U.S. knees inactive necessitate further improvement. He besides noted a “record twelvemonth of halfway replacements globally” and continued adoption of the company’s robot-assisted platform. In Advanced Wound Management, helium described 2025 show arsenic solid, with maturation driven by Advanced Wound Devices and “C.”

→ 5 Hot Buys Ready to Spring Higher successful March

Surgical Centers, Med-Tech Stocks Up On Pent-Up Surgical Demand

Chief Financial Officer John Rogers reported fourth-quarter gross of $1.7 billion, up 6.2% connected an underlying ground and 8.3% reported, including a 210 ground constituent tailwind from overseas exchange. He noted the 4th included 1 other trading time year-over-year; connected an mean regular income basis, maturation was 4.5%.

Growth was described arsenic broad-based crossed regions. Rogers said U.S. gross grew 5.6%, different established markets roseate 7.2%, and emerging markets accrued 6.4%. Excluding China, underlying maturation was 7.2%.

→ MarketBeat Week successful Review – 02/23 - 02/27

Read Entire Article